SIRION Biotech GmbH
SIRION Biotech is Europe's leading commercial supplier of viral vector technologies for gene & cell therapy, target validation and vaccination studies.
Since beginning sales in 2007, SIRION’s mission has been to change the paradigm for viral vector supplies. It has the ability to custom modify and supply all common viral vector types (AAV, lentivirus and adenovirus) within a matter of weeks. Its manufacturing network allows dependable supply of virus titers and quantities from preclinical and animal research levels to clinical testing.
Several of its next-level innovations are available for out licensing to industrial clients.
Viral vector services
SIRION’s core expertise lies in the customized design and generation of virus vectors for genetic engineering of mammalian cell systems. With its comprehensive portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. This maximizes researchers’ experimental freedom when designing cell based projects and ensures maintenance of high quality standards.
SIRION can supply all three of the most commonly used virus systems for gene manipulation:AAV customization
Adeno-associated viruses (AAV) possess biological characteristics that make them one of the most promising avenues for in vivo application of viral vectors. They allow long-lasting gene over expression and-knockdown to assess phenotypic impact of a gene at the level of the living organism.
AAVs feature a lack of apparent pathogenicity, along with long-term gene expression in vivo of up to one year.
SIRION Biotech undertakes customized construction and manufacture of AAV serotypes 1-6 and1.2 in less than eight weeks, guaranteeing a minimum of 1-5 x10E12 viral particles. This range allows for tissue targeted expression control that is further increased by a selection of cell specific promoter strategies. The service enables the integration of virtually any desired expression construct within the vector’s cloning capacity of 4.5 kb. Inducible systems are in development.
SIRION’s highly purified and concentrated AAVs enable non-toxic in vivo gene delivery and comply with German BL-1 (S1) safety regulations, which are among the most stringent in the world.Lentivirus customization
Lentiviruses provide researchers with an ideal method for fast, efficient and cost effective generation of stable cell models.
SIRION Biotech`s lentiviral vector technology allows for constitutive as well as inducible gene modification. It offers a reliable system for strong gene over expression and –knockdown, with custom cloning-to-virus delivery times in less than four weeks. Inducible LV constructs enable the experimenter to work with otherwise unattainable, cell toxic gene targets or shRNA sequences, adding to the range of potential applications of this vector system.
SIRION`s in house optimized LV vectors enable the generation of expression-homogeneous, stable cell models without the necessity to waste time on additional clonal selection steps post-transduction.Adenovirus customization
Recombinant adenovirus particles (AVs) are the viral vector of choice for strong, transient gene over expression and–knockdown.
SIRION Biotech`s patented adenovirus generation system is based on bacterial artificial chromosome (BAC) technology allowing for custom AV generation in under five weeks. SIRION uses replication deficient E1/E3 deleted stereotype 5 recombinant AVs that comply with all official safety criteria. SIRION`s service allows for virtually any vector customization within a range of 7.5 kb.
SIRION AVs enable proficient cell type accessibility for highly efficient transduction of hard to transfect cells, even primary cells, without species limitations.
SIRION Biotech offers advanced services to complement their manufacturing platform. The flexible combination of all these service lines makes SIRION a valuable partner in preclinical target research and the development of clinical collaborations.
Clinical applications and development
SIRION Biotech brings innovative technologies into collaborations with high clinical relevance, ready to be spun out with specific data and new investors.
LentiBOOST™, clinical transduction enhancer for ex-vivo modification of hematopoietic cells has been a crucial element of SIRION’s support of clinical trials since 2016. The compound is currently used in several clinical trials (phases I/II and phase III) in Europe and the US to improve hematopoietic gene therapies and Car-T cell applications.
NextGen AAV projects aim to improve AAV capsids for clinical trials. By using unique AAV libraries and capsid-evolution strategies, SIRION can design capsids for close to any specified application, cell or tissue type.Ad19a
The novel AV serotype Ad19a, the first openly accessible subtype D adenovirus, has been made possible by SIRION's BAC technology. This serotype provides a true alternative to Ad5 and Ad2 serotypes, can transduce human-derived cells (myoblasts, myotubes and dendritic cells) and, with a low prevalence of pre-immunization in the human population, carries great potential to become the future vehicle for virus driven vaccinations.
History and structure
Dr. Christian Thirion founded SIRION Biotech while also leading a research team at the Neurology-focused Friedrich-Baur-Institute in Munich-Grosshadern. Dr. Thirion is SIRION’s Chief Technology Officer and an eminent authority on cellular analysis and modeling, who has worked on cell modeling projects for more than 100 clients, critically shortening pre-clinical cycles in drug compound discovery.
SIRION is based at Martinsried, just outside Munich, with local representations in the USA, France, Japan, South Korea and Israel. Commercial arrangements range from fee-for-service to large scale R&D collaborations and milestone and licensing arrangements. The SIRION business model has achieved consistent 70% annual revenue growth since 2007.
The company is privately owned and has over the years raised funds from government and private investors. SIRION maintains close connections with scientific collaborators at academic institutions across Germany as well as a wide network of alliance companies and distribution partners.
To learn more about SIRION Biotech's services and capabilities and how they can assist your business, please contact the supplier.
- > Molecular biologist Dr. Carl Christel to head SIRION Biotech in USA
- > SIRION Biotech participates in combined ABC of AAV offer at ESGCT 2019 Barcelona
- > RNAiONE™ algorithmic identification of shRNA sequences
- > SIRION records 100% revenue growth
- > Engineered lentiviral vectors for custom cell models
- > SIRION highlights France as leading force in gene and cell therapy
- > NIAID allergy institute chooses SIRION LentiBOOST™ technology to strengthen SCID-X1 immunodeficiency study
- > SIRION Biotech Expands North American Presence by Opening New Site at Cambridge, MA.
- > SIRION Biotech strengthens USA links with new partnership and manufacturing site
- > New success for SIRION Biotech vaccination candidate Ad19a/64
- > SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study
- > SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16
- > SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume
- > Customized adenoviral vectors (AVs)
- > SIRION Biotech expands business and ideas
- > SIRION Biotech announces preclinical vaccination success
- > Modifying iPS Cells With Lentivirus to build more robust disease models
- > ProVector™: Protecting production cells from problematic transgene expression
- > SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe
- > SIRION Biotech bringing latest viral vector insights to ELRIG Drug Discovery ’15
- CRO, CMO, CRAMS & CDMO
- Clinical Trials & Studies
- Drug Discovery
- Manufacturing & Production
- Pre-Clinical Research